Charles Albright, Ph.D. Chief Scientific Officer Charlie is Chief Scientific Officer of Editas Medicine. He joined Editas Medicine in August 2016 and is responsible for leading the team that is translating the promise of genome editing into a broad class of transformative genomic medicines.